SCHEMBL13222833

SCHEMBL13222833

CC(C)(C)[C@@H](CO)NC(=O)c1cc2cc(NC(=O)Cc3ccc(O)c(O)c3)ccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ PYGL P06737 9/20 0.41
▸ BCHE P06276 2/20 0.41
▸ ACHE P22303 2/20 0.41
▸ NHERF1 O14745 1/20 0.41
▸ NPC1 O15118 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ ALB P02768 1/20 0.39
▸ IL2 P60568 1/20 0.39
▸ ANO1 Q5XXA6 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ MMP13 P45452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13204716 0.85 MAPT (0.57) NPC1KDM4EMAPTRAB9A
SCHEMBL15099971 0.78 KDM4E (0.57) PYGLNHERF1NPC1KDM4EMAPT
SCHEMBL14845704 0.76 TP53 (0.54) NPC1KDM4EMAPTEGFRRAB9A
SCHEMBL19085805 0.74 EGFR (0.44) PYGLNHERF1NPC1KDM4EMAPT
SCHEMBL12741547 0.73 KDM4E (0.52) NPC1KDM4EMAPTRAB9A
SCHEMBL13202977 0.73 KDM4E (0.52) NPC1KDM4EMAPTRAB9A
SCHEMBL12741289 0.73 KDM4E (0.52) NPC1KDM4EMAPTRAB9A
SCHEMBL108018 0.69 BCHE (0.63) BCHEACHEKDM4EMAPT
SCHEMBL5641332 0.68 MEN1 (0.72) NPC1MAOBRAB9A
SCHEMBL19427518 0.65 BCHE (0.64) BCHEACHEKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776905-B2 including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-17 — — US disclosed
Send feedback